Our drug sensitivity analysis revealed that LGALS1 expression was correlated with sensitivity to several FDA-approved drugs, including zoledronate and staurosporine, highlighting the potential for repurposing existing drugs to target this immune regulatory protein in GBM. The gene discussed is LGALS1; the disease is glioblastoma.